DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for hyper-IgE syndrome — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHyper-IgE syndrome maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hyper-ige syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
signal transducer and activator of transcription 3 (STAT3) — STAT3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2-{[(5s,8s,10ardrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6NJS · 2.7 Å · ligand [(2-{[(5S,8S,10aR)-3-acetyl-8-({(2S)-5-amino-1-[(diphenylmethyl)amino]-1,5-dioxopentan-2-yl}carbamoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocin-5-yl]carbamoyl}-1H-indol-5-yl)(difluoro)methyl]phosphonic acid (non-preferred name) (KQV). Experimental structure, not a prediction.
What the evidence adds up to
A 1988 case report describes a patient with hyper-IgE syndrome who underwent 60 plasmapheresis sessions over two years alongside cytotoxic immunosuppressive drugs. The severe dermatitis of eight years became almost completely inactive, and the circulating IgE level fell by 73%. The ratio of CD4+ to CD8+ T lymphocytes, which was elevated before treatment, dropped to subnormal. The authors attribute the improvement to the combined reduction of IgE-producing lymphocyte populations and the direct removal of circulating IgE and possibly IgE-potentiating factors.
A 2016 report on Meige's syndrome is not relevant to hyper-IgE syndrome. A 2025 review notes that hyper-IgE syndromes are a heterogeneous group defined by eczema, recurrent infections, and markedly elevated serum IgE. The identification of new molecular defects has complicated diagnosis, and non-immunological connective-tissue abnormalities contribute to significant comorbidities. The review states that the primary management objectives are infection control, prevention of long-term complications, and improvement of quality of life.
No controlled trials, no randomised data, and no validated drug regimen exist for hyper-IgE syndrome. The 1988 case is a single patient treated with an intensive, invasive protocol that has not been replicated. The 2025 review offers no new treatment data. What is missing is any prospective trial, any standardised outcome measure, any patient stratification by the newly identified genetic defects, and any funding for a therapy that would need to be tested against the natural history of a rare, heterogeneous disease.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Clinical Apheresis · 1988 · 12 citations
Remission of hyper‐lgE syndrome treated with plasmapheresis and cytotoxic immunosuppression
AbstractA patient with a hyper-IgE syndrome was treated with 60 plasmaphereses over a period of 2 years in conjunction with cytotoxic immunosuppressive drug therapy. During this time her severe dermatitis of 8 years' duration became almost completely inactive, and her circulating IgE level was reduced by 73%. An elevated pretreatment ratio of CD4+/CD8+ T lymphocytes fell to subnormal. The beneficial results of treatment may be attributed to the reduction of lymphocyte populations responsible for IgE production by the combined action of plasmapheresis and of cytotoxic drugs as well as the direct effect of removal of circulating IgE and possibly IgE-potentiating factors.
AbstractMeige's syndrome consists of idiopathic blepharospasm and oromandibular dystonia. The exact etiology is not known and various hypotheses have been proposed for its causation. The hypothesis suggesting dopaminergic and cholinergic hyperactivity is most widely accepted. There is no curative drug for Meige's syndrome although a variety of treatments have been proposed. We report a case which responded to tetrabenazine.
ImmunoTargets and Therapy · 2025 · 2 citations · open access
Understanding and Managing Hyper IgE Syndromes
AbstractHyper-IgE syndromes represent an increasingly recognized and heterogeneous group of disorders characterized phenotypically by eczema, recurrent infections, and markedly elevated serum IgE levels. The identification of novel molecular defects in recent years has complicated definitive diagnosis, underscoring the genetic and clinical diversity of this group. In addition to immunological abnormalities, non-immunological manifestations-particularly those affecting connective tissue-contribute to significant comorbidities. The primary objectives of management are to control infections, prevent long-term complications, and improve quality of life. In this review, we summarize the clinical and laboratory features of disorders currently classified under hyper-IgE syndromes according to the most recent International Union of Immunological Societies framework and provide perspectives on their management.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
